

Abemaciclib monarchE

PRELIMINARY SCORE

CURATIVE


DFS

Scoring of iDFS on the same basis as DFS


NON-CURATIVE

ADJUSTMENTS

Quality of life





?




QoL data pending


Serious and disabling adverse effects





Other adjustments





Abemaciclib monarchE

SCORE

CURATIVE

A

Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE

Overall Survival

Progression-Free Survival

Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate

Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Therapeutic Indication: Adjuvant treatment of adult patients with hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence
Experimental Arm: Abemaciclib + Standard endocrine therapy (aromatase inhibitors and/or antiestrogens with or without ovarian suppression)
Control Arm: Standard endocrine therapy

